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Abstract: 
 
Background: Door-needle-times of 20 minutes to stroke-patients with intravenous-tissue-
Plasminogen-Activator (iv-tPA) are feasible when Computer Tomography (CT) is used as first-line of 
brain-imaging. Magnetic Resonance Imaging (MRI)-based assessment is more time-consuming but 
superior in detecting acute ischaemia. The certainty with which stroke-physicians prescribe or 
refrain from iv-tPA-treatment to CT versus MRI-examined patients has not previously been studied.   
The aim was to determine the effect of a primary imaging-strategy of CT or MRI upon clinicians’ 
certainty to prescribe or refrain from giving patients with suspected acute stroke iv-tPA.  
 
Method: Consecutive patients with suspected stroke were quasi-randomized to either CT or MRI-
based assessment prior to potential iv-tPA-treatment.  
The influence of 1) the clinical-findings and 2) the image-findings and 3) the certainty at which the 
stroke-physician prescribed or refrained from giving iv-tPA-treatment were assessed with Visual-
Analogue-Scales.  
Predictors of treatment-certainty were identified with a random-effect-model.  
 
Results: Four-hundred-forty-four consecutive patients were quasi-randomized. MRI influenced the 
final treatment-decision more than CT (p=0.002). Compared to CT-examined patients (mean VAS-
score 8.6, SD± 1.6) stroke-physicians were significantly more certain when prescribing or refraining 
from giving iv-tPA to MRI-examined patients (mean VAS-score 9.0, SD ±1.2) (p=0.014). No 
differences in modified Ranking Scale or mortality were detected at three months in CT versus MRI-
examined iv-tPA-treated patients.  
 
Conclusions:  Stroke-physicians were significantly more certain when prescribing iv-tPA to MRI-
examined stroke-patients and MRI influences the final treatment-decision significantly more 
compared with CT— though no difference in mortality and functional outcome at three months 
were detected between CT and MRI-examined patients treated with iv-tPA.    
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Introduction: 
Stroke-teams have worked assiduously to reduce Door-Needle-Time (DNT) from hospital-admission 
to administration of intravenous-thrombolysis (iv-tPA) for acute stroke-patients (1-8) as the 
treatment-efficacy is time-dependent hence the saying “time is brain” (9).  
Compared to Computer Tomography (CT), Magnetic Resonance Imaging (MRI) is more likely to 
show early signs of acute cerebral ischemia (10, 11) but is more time-consuming and unfeasible in 
patients with ferromagnetic-implants, pacemakers, claustrophobia, physical unrest and large body-
size (12). As the efficacy of iv-tPA is time-dependent (13), MRI must impart clinical benefits to 
justify as primary image-modality prior to iv-tPA-administration.  
 
As MRI-based-assessment is superior in confirming early signs of ischaemia and identifying some 
stroke-mimics it could add clinical information especially in situations with diagnostic uncertainty. If 
MRI were to be used as first-line imaging prior to iv-tPA then one could speculate that stroke-
physicians would feel more certain about their decision to prescribe iv-tPA to these patients.  
 
Although physicians’ clinical decisions-making have been studied (14-19), studies on factors which 
influence stroke-physicians’ decision-making about whether or not to give iv-tPA-treatment are 
scarce (20). The certainty with which they prescribe or refrain from iv-tPA-treatment has not 
previously been studied in a clinical setting.   
 
We conducted a randomized clinical trial to answer the question; is CT or MRI-head-scan the best 
radiological image-modality to use prior to iv-thrombolysis for acute stroke-patients?  Image-
feasibly and DNT for CT and MRI-based iv-tPA-treatment have been reported (12); the median DNT 
for MRI-examined patients was 11 minutes longer than for CT-examined patients and 42.0% of the 
MRI allocated patients were not eligible for MRI due to contraindications or unstable medical 
conditions. 
 
The aims of this sub-study were to assess the certainty with which stroke-physicians prescribed or 
refrained from giving iv-tPA-treatment to acute stroke-patients randomized to CT or MRI-based 
assessment and to evaluate the influence of the clinical and radiological information available upon 
the iv-tPA-decision. 
 
Method:  
Setting: 
All patients from the Region of Copenhagen (1.7 million inhabitants) presenting with symptoms of 
acute stroke within 4.5-hours from symptom-onset were brought to Bispebjerg-Frederiksberg-
University-Hospital on even dates after pre-notification by the emergency-service. Patients were 
treated with iv-tPA and endovascular-treatment if eligible. The patients were brought directly to a 
dedicated stroke-room within the Department of Radiology, bypassing the Emergency-Department. 
Upon arrival, the patients were evaluated by a pre-notified stroke-team working according to a 
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fast-track-setup and comprising a stroke-physician, a stroke-nurse, a porter, a neuro-radiologist and 
two radiographers. The stroke-physician was either a neurological resident in the final six month of 
training (n=14, assessing 12.6% of the patients), a neurological consultant (n=4, assessing 12.8% of 
the patients) or a senior-stroke-neurological consultant (n=6, assessing 74.5% of the patients).   
The stroke-physician initiated all examinations, informed the patients about iv-tPA-related 
benefits/risks and advised the patients to accept the iv-tPA-treatment if eligible. For patients who 
were able to consent, the final decision of accepting the treatment was their choice.  
 
Randomization:  
From December 2013 to November 2015, all consecutive patients (>17 years) with suspected acute 
stroke and admission during daytime on weekdays (8am-3pm) were quasi-randomized based on 
the day of admission to receive CT or MRI as the initial imaging-strategy. An equal number of days 
were predefined as CT and MRI-days and posted in the Department of Radiology at least 6 months 
in advance.  
A radiological Standard-Operational-Procedure (SOP) was followed but allowed for cross-over 
between the CT and MRI in case of predefined contraindications, absolute medical need of the non-
allocated image-modality, physical unrest or patients in a critical condition not enabling MRI.   
All MRI-allocated patients were systematically assessment for MRI-eligibility.  
Due to the clinical setup, blinding of neither patients nor stroke-team-members was possible. 
 
Sample size:  
As no previous comparable studies have been conducted, sample-size was estimated based on 
expected differences in DNT of CT-and MRI-based examination. With a least clinically relevant 
difference of 10 minutes, Standard-Deviation at 20 minutes, alpha two-tailed at 0.05 and beta at 
90%, the total number of participants was estimated at 172 patients. Nevertheless, the sample-size 
was extended in order to allow for analysis of secondary outcome-measures. 
 
Outcome: 
For each patient, the stroke-physicians completed an anonymous questionnaire using Visual-
Analogue-Scales (VAS) to indicate 1) the influence of the clinical information obtained on the final 
decision to prescribe or refrain from giving iv-tPA-treatment 2) the influence of the radiological 
image-information obtained on the final decision to prescribe or refrain giving from iv-tPA-
treatment and 3) the level of certainty of prescribing or refraining from iv-tPA.   
The VAS was constructed as 10-cm horizontal-lines. The two extremes were placed at each end of 
the lines; zero indicated the lowest possible influence/most pronounced uncertainty while 10 
indicated the highest possible influence/certainty. To answer the three questions, the stroke-
physicians marked each line.  
 
Imaging:  
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If allocated to CT, patients had a non-contrast head-CT followed by CT-angiography and if allocated 
to MRI a head-DWI, T2-FLAIR, GRE-T2* and an arterial Time-of-Flight (TOF)-angiography.   
MRI were performed in 1.5T (GE-Sigma) or 3T (Siemens-Magnetom-Verio) scanners according to 
availability and CT on a Philips Brilliance 64-slice scanner. MRI-safety was adhered to according to 
International guidelines.  
 
The imaging was assessed twice; first prior to iv-tPA-administration to rule out pathology 
contraindicating iv-tPA-treatment and later systematically according to a predefined research-plan.  
 
In order to categorize the image-findings which either supported or discouraged use of iv-tPA three 
binary radiological scores were constructed and assessed for each patient of; 1) radiological signs 
for iv-tPA-treatment, 2) radiological signs against iv-tPA-treatment and 3) radiological signs of 
increased risk of iv-tPA-induced Intracranial Hemorrhage (ICH). This constituted the basis of the 
stroke-image-reading and replicates what was available prior to the stroke-physician’ treatment-
decision. For MRI-examined patients, the first score was positive in case of DWI-positivity and/or a 
large-vessel-occlusion of clinical relevance combined with FLAIR-negativity and for CT-examined 
patients in case of lack of deep hypoattentuation and/or large-vessel-occlusion or a dense-artery of 
clinical relevance.  
The second score was positive in case of ICH, hemorrhagic-transformed infarct, signs of tumor, 
ischaemia involving >1/3 of the middle-cerebral-artery-territory or MRI-FLAIR-positivity. Further 
arteriovenous-malformations, aneurysms, subacute infarctions and signs of traumatic brain-injury 
were included as radiological contraindications.  
The third score assessing signs of increased risk of iv-tPA-induced ICH included moderate to severe 
leucoaraiosis (Fazekas 2-3) that has been shown to double the risk of iv-tPA-induced ICH (21).  
Though lack of association between intracerebral microbleeds and iv-tPA-induced symptomatic ICH 
recently has been reported (22), microbleeds are still considered a risk-factor of iv-tPA-induced ICH 
by many clinicians (23) and were thus included as a risk-factor.  
 
Statistical analysis: 
Continuous data were compared with students-t-tests and categorical with Chi-square tests. A 
random-effect-model allowing for the cluster-effect of the stroke-physicians each seeing more than 
one patient was constructed to identify predictors of increasing treatment-certainty. 
Patients with missing VAS-scores were not included when VAS-scores were compared or predictors 
of treatment-certainty were tested.  
Tests were done according to the conducted imaging (per-protocol) and not according to allocation 
(intention-to-treat) as the stroke-physicians’ decisions were based on the conducted imaging.  
The following predictors were tested; age/gender of the patient, conducted image-modality, NIHSS, 
pre-onset modified-Rankin-Scale (mRS), seniority(late neurological resident, neurological consultant 
or senior-neurological-stroke consultant), the time-interval to arrival of the next patient and the 
number of patients evaluated during the shift (accounting for the work-intensity), if iv-tPA was 
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prescribed, the image and clinical influence on the treatment-decision (VAS-scores) and finally the 
three previous mentioned constructed binary radiological scores.  
A two-sided P-value <0.05 were considered significant.  
 
Statistical analyses were performed using IBM-SPSS-Statistics (Version 20.0, IBM-Corp, Armonk, NY, 
USA) and SAS-Enterprise (Version 7.11, Cary, NC, USA).     
 
The registry was approved by the Copenhagen-Regional-Ethics-Committee (H-4-2013-118), the 
Danish-Data-Protection-Agency (2007-58-0015) and registered at clinicalTrials.gov (NCT02780843). 
 
Results: 
Four-hundred-forty-four patients were admitted with suspected stroke within 4.5 hours from 
symptom-onset; 225 patients were quasi-randomized to CT and 219 patients to MRI (fig 1.).  
Due to cross-overs between CT and MRI, 310 patients had a CT-scan and 134 patients had MRI.  
MRI was not performed in 48.9% of MRI-allocated patients due to: MRI-contraindications (23.7%), 
physical agitation (7.8%), unstable medical conditions (6.4%) and organizational issues (6.8%); 
further details have been published elsewhere (12).  Twenty-two (9.8%) of the CT-allocated patients 
had MRI; 6 (2.7%) patients due omission of X-ray-exposure of pregnant/very young patients and 16 
(7.1%) in need of diagnostic clarification of suspected stroke-mimics due to atypical clinical 
presentation. 
The median DNT for MRI-examined were 11 minutes longer than for CT-examined patients (table 
1); further details on DNT has been reported elsewhere (12). 
A total of 140/444 patients received iv-tPA-treatment corresponding to 33.5% of the male patients 
and 29.7% of the female patients, (p=0.449). 
Baseline-characteristics according to allocation are presented in table 2 and conducted imaging in 
table 3.   
The median NIHSS on admission did not differ between CT (6 IQR 9.25) and MRI-allocated (6 IQR 
10) iv-tPA-treated patients, p=0.773. But the NIHSS on admission was significantly higher for the iv-
tPA treated CT-examined (7 IQR 10) than for the MRI-examined patients (4 IQR 4), p=0.007. 
For CT versus MRI-examined iv-tPA-treated patients, mortality, median mRS and chance of 
independent living at 3 months did not differ (table 4). The frequencies of symptomatic ICH (sICH) 
at 24 hours are further reported (table 4).   
For 111 (25.0%) patients, the stroke-physicians did not fill-out the questionnaires with the three 
VAS-based questions (fig. 1); no significant difference in missing questionnaires were detected 
between CT (61 patients=27.1%) versus MRI-allocated patients (50 patients=22.8%) (p=0.352) nor 
between CT (81 patients=26.1%) versus MRI-examined patients (30 patients=22.4%) (p=0.474). The 
uncompleted questionnaires were not associated with the seniority of the stroke-physicians - 
(p=0.363).  
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The image and clinical contribution: 
The stroke-physicians indicated that MRI compared with CT had a significantly larger influence on 
the final decision to prescribe or refrain from iv-tPA-treatment (p=0.002) (table 5). 
When asked to indicate the influence of the clinical information available on the final decision, no 
significant difference were detected between the CT and the MRI-examined patients, p=0.915 
(table 5); indicating that the clinical information available for CT-examined patients did not gain 
compensatory relevance in spite of the less pronounced influence of imaging in CT-examined 
patients.  
The certainty to prescribe or refraining from iv-tPA:  
The stroke-physicians were significantly more certain when they prescribed or refrained from 
thrombolysis in MRI-examined patients compared to CT-examined patients, p=0.014 (table 5).  
However, when the treatment-certainty was adjusted for; age/gender of the patient, NIHSS, pre-
onset mRS, seniority of the stroke-physician, work-intensity of the shift, if thrombolysis was 
prescribed, the VAS-based imaging and clinical contribution on the final treatment-decision and the 
three binary radiological scores, the image-modality no longer predicted the level of treatment-
certainty (p=0.125) (table 6). Further stroke-physicians were significantly more certain when 
treating male patients (p=0.046) and were more doubtful if iv-tPA had been prescribed (p=0.001) 
(table 6). An increasing VAS-score of the radiological image-contribution (p=0.0001) as well as the 
clinical information obtained (p=0.0001) on the final decision both predicted increasing levels of 
treatment-certainty (table 6). Seniority of the stroke-physician did not predict the treatment-
certainty (table 6). 
Discussion: 
In this quasi-randomized study, MRI contributed with significantly more diagnostic value than CT-
scans to help stroke-physicians decide whether or not to prescribe iv-tPA-treatment. Stroke-
physicians further felt significantly more certain when they prescribed or refrained from giving iv-
tPA-treatment to MRI-examined patients though no difference in mortality and functional outcome 
at three months were detected between CT and MRI examined patients.    
This randomized trial was conducted in a stroke-unit with a well-established iv-tPA-service 
performing approximately 300 iv-tPA-treatments annually.   
We are not aware of any previous randomized studies comparing the level of treatment-certainty in 
CT versus MRI-examined patients.  
The strengths of this study include the novelty of comparing CT and MRI in an acute randomized 
clinical setting, the substantial number of included consecutive patients and the prospectively 
collected data regarding the treatment-decision.   
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Apart from a significantly higher number of male patients in the MRI-allocated group, the quasi-
randomization allocated the patients into two well-balanced groups. But due to cross-overs 
between CT and MRI, the CT and MRI-examined groups differed in both numbers, baseline-
characteristics and long-term outcome; a scenario that reflects a true clinical setting with patients 
with diverse clinical presentations and inherent MRI-contraindications. For this sub-study only a 
lower age-limit were applied to secure a true consecutive and unselected cohort of patients 
presenting with symptoms of acute stroke; with discharge-diagnosis of stroke as well as stroke-
mimicking conditions.  
Due to MRI-contraindications, physical agitation, unstable medical conditions and organizational 
issues MRI was not feasible in 48.9% of the MRI-allocated patients, consistent with Singer et al (24); 
details has been published elsewhere (12). To accommodate the need for cross-over, the degree of 
certainty is reported as per-protocol and not as intention-to-treat. Due to the need for cross-overs 
there is a selection-bias.    
There is a non-response-bias as for 111 (25%) patients whose VAS-based-questionnaires were not 
filled out by the stroke-physicians. No significant difference in missing VAS-formularies was 
detected between CT versus MRI allocated/examined patients or between young and more 
experienced stroke-physicians. We did not identify whether missing questionnaires in particular 
occurred on busy shifts or the patients for whom the questionnaires were not filled out differed 
from the patients with completed questionnaires. We are not able to establish why the 
questionnaires were not replied. 
 
The trial was conducted in a comprehensive acute stroke-unit in a Danish public hospital treating 
patients with mixed socioeconomic-status. No private acute stroke-services exist.  
We believe that our results generalize to acute stroke settings outside Denmark as two important 
decisions have to be made in patients presenting with symptoms of acute stroke, regardless of the 
institutional set-up. First, is the patient suffering from acute cerebral ischaemia and second is the 
patient eligible for iv-tPA-treatment?  
Our patient-cohort consists of a higher number of patients with mild strokes as well as stroke-
mimics which potentially induces a higher degree of treatment-uncertainty compared to a cohort of 
severe strokes with a higher iv-tPA-treatment-related benefit/risk-ratio. The reported difference in 
treatment-certainty might have been different if the trial had been conducted in a setting with 
more selected patients: i.e a higher frequency of severe strokes and less stroke-mimics.    
 
A general presupposition of MRI as golden-standard (10, 11) may have affected the stroke-
physicians’ perception of MRI compared to CT. In case of MRI-allocation, both the assessment for 
MRI-specific radiological signs as well as the psychological-effect of knowing that “the best” 
available radiological examination had been conducted could have enhanced the perceived 
certainty. It would have been relevant to include each stroke physician’s general perception of 
whether MRI or CT scan is the best imaging-modality for iv-tPA-decision.  
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We could have included well-established CT-specific predictors of early ischaemia (30, 31); but our 
population presented early after onset and predominantly with mild strokes. However, of the three 
radiological predictors only image confirmed contraindications differed significantly between the 
two groups (table 3), caused by MRI-detected FLAIR-lesions which indicated potential non-hyper-
acute cerebral ischaemia.   
 
Due to the clinical setup, blinding of neither patients nor stroke-team-members was possible. In 
addition, the quasi-randomized setup did not allow for concealment.   
Although the VAS-based questions were not pre-validated, VAS is widely used for anxiety (25), pain 
(26) and headache (27), the latter daily used by Danish neurologists. We assumed that the daily use 
of VAS would easily facilitate the usage of the VAS-based questions. As physicians may not always 
be as certain as patients presume them to be (17, 28), we had not anticipated the high mean 
reported VAS-scores (table 4). The stroke-physicians marked the VAS-scales anonymously and 
should thus unimpeded be able to answer the questions truthfully.  
Similar to our high degree of treatment-certainty, a Canadian survey reported that iv-tPA-
prescribing physicians recognized the importance of diagnostic uncertainty though only 4% 
frequently experienced uncertainty (29). 
 
Decision-making not only relies on the presentation of symptoms and the probability of disease but 
is also influenced by non-medical factors regarding the patient, the physician, the staff and the 
practical setting (14, 15, 29). Our study was not designed to test further predictors.  
Although male and female patients were equally likely to receive iv-tPA-treatment, male gender 
predicted a significantly higher level of treatment-certainty. Female patients are significantly less 
likely to accept iv-tPA-treatment and less certain when involved in the treatment-decision (30). If 
the female patients were more doubtful, the hesitation may have affected the stroke-physicians’ 
certainty. We did not register socioeconomic-status or language-barriers caused by ethnicity, 
reduced consciousness or aphasia/dysarthria; conditions that potentially affect the communication 
and thus the treatment-decision. Nor did we register if the patient accepted the advised treatment, 
if the patient participated in the decision-making or was so severely affected that the treatment-
decision was at the discretion of the stroke-physician alone.  
The stroke-physicians were significantly more certain when the iv-tPA-decision followed a MRI-
examination; but when adjusted for baseline-characteristics and the radiological detectable CT and 
MRI-pathology available in the acute setting undertaking a MRI no longer predicted a significantly 
higher level of certainty.  
 
Use of MRI as first-line of imaging induced a median treatment-delay of 11 minutes compared to 
when patients had a CT-scan prior to iv-tPA-treatment. Despite the MRI-induced treatment-delay, 
we did not detect a difference in mortality or functional outcome at three months between CT and 
MRI-examined patients. Table 1 reports DNT according to allocation and the actual imaging 
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performed. The median DNT for all MRI-allocated patients were 30 minutes but four minutes longer 
for the subgroup of MRI-allocated patients who had MRI as first-line of imaging. Cross-over from 
MRI to CT on average decreased DNT —likely due to a shorter image protocol and lack of MRI-
safety procedures.  
When comparing patient-baseline-characteristics according to allocation and actual imaging 
performed (table 2 +3), it is evident that the subgroup of MRI-allocated patients who had crossover 
to CT in general were of increased age and stroke severity, of poorer pre-onset functional status 
and to a higher extend were suffering from hypertension. Though lack of balance in baseline-
characteristics between CT and MRI-examined patients is in favor of a better outcome for the MRI-
examined patients, no differences in long-term outcome were reported (table 4).  
 
The treatment-delay in MRI-examined patients might leave more time for the treatment-decision 
and could thus potentially contribute to a high level of treatment-certainty in MRI-examined 
patients — though the majority of the additional time spend was attributed to MRI-safety 
procedures involving the stroke-physician. The random-effect-model further indicates that the 
work-intensity of the stroke-physician did not affect the degree of treatment-certainty reported.   
  
Our study was not designed to assess whether the results of the imaging in fact changed the stroke-
physicians’ treatment-decisions. We are only able to assess their level of certainty of the final 
treatment-decision.  
The mechanisms of refraining from treatment versus prescribing treatment may be different but 
due to lack of power certainty to give iv-tPA and certainty to refrain from iv-tPA was condensed 
into a single category.   
 
Further one must consider the moderate difference of 0.4 VAS score of certainty between the CT 
and MRI-examined patients; although statistical significant on group level, the difference is small. 
The question remains, are the differences of clinical relevance?  
 
A borderline-significant higher frequency of CT-examined patients had iv-tPA-treatment compared 
to MRI-examined patients but in addition also presented with significantly higher stroke-severity on 
admission (table 3).  
Our patient-cohort consists of relatively mild strokes and thus perhaps represents the type of 
patients in whom most uncertainty exists regarding the iv-tPA-treatment-decisions. The benefit-
harm-ratio in patients with mild strokes is less favorable than in patients with more severe 
neurological symptoms. Mild strokes thus potentially introduces a higher degree of uncertainty on 
whether one should prescribe or refrain from treatment in order to prevent treatment-induced 
complications. Due to cross-overs, the patients who had MRI presented with less pronounced 
neurological symptoms and a significantly higher frequency of stroke-mimics (table 3). 
Consequently it is reasonable that fewer MRI-examined patients received iv-tPA treatment 
compared to CT-examined patients.   
Our trial was not designed to establish the decisive diagnostic cause of the treatment-decision.   
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It would be interesting to know whether MRI mostly reinforces the decision not to treat patients 
who otherwise would have been treated if examined with CT. The frequency of relative radiological 
iv-tPA-contraindications were significantly higher in the MRI-examined group of patients (table 3) 
which potentially could have induced a reluctance to administration of iv-tPA.   
 
As the MRI-examined patients presented with a more heterogeneous clinical profile and thus 
potentially posed an increased diagnostic challenge, one would expect that the stroke-physicians 
would indicate a low degree of treatment-certainty. But as indicated by the significantly higher 
contribution of MRI on the treatment-decision (table 5), it is likely that MRI-detectable signs of 
disease (e.g lack/presences of acute intracranial ischemia) induced a feeling of making the correct –
treatment-decision.    
We do not know what the increase in treatment-certainty means in terms of the adequacy of 
treatment-decision and how the increased certainty translates into treatment-outcome potentially 
affecting complication rates and long-term physical outcome.  
Mortality and mRS at 3 three month did not differ between iv-tPA-treated CT versus MRI-examined 
patients.  
Due to lack of power, a direct group-comparison of sICH in our CT and MRI-examined patients is not 
applicable but the reported frequency for both CT and MRI-examined patients elaborates 
previously reported frequencies (1.8-9.5% (4, 31-38)) of sICH in iv-tPA-treated patients.  
We may thus buy certainty with MRI, but what do we gain with certainty and what is the cost?  Our 
trial was not designed to fully account for this aspect.   
To conclude stroke-physicians were significantly more certain when prescribing iv-tPA to MRI-
examined stroke-patients and MRI influences the final treatment-decision significantly more 
compared with CT— though no difference in mortality and functional outcome at three months 
were detected between CT and MRI examined patients treated with iv-tPA.    
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Table 6. Random-effect-model predicting the iv-tPA-treatment-certainty-level.   
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Figure 1, Flow-chart  
 
 
 
 
 
 
 
 
 
444 Assessed for eligibility
444 Randomized 
225 Assigned to receive CT-assessment
203 Received CT-assessment
22 Received MRI-assessment
61 Lost to follow-up 
(Missing VAS-questionnaires)
164 Included in the analysis
61 Excluded from analysis
219 Assigned to recive MRI-assessment
112 Received MRI-assessment
107 Received CT-assessment
50 Lost to follow-up
(Missing VAS-questionnaires)
169 Included in Analysis 
50 Excluded from analysis
0 Excluded
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Allocation Conducted imaging  Allocation, cross-overs excluded 
CT (n=75) MRI (n=65) p CT (n=107) MRI (n=33) p CT (n=73) MRI (n=31) p 
22 (15.5) 30.0 (14.0) 0.004 23.0 (16.5) 34 (14.0) 0.001 22 (15.0) 34 (14.0) 0.001 
 
Table 1. Median Door-to-needle-times (DNT) in minutes (IQR) according to allocation, actually 
conducted image-modality (after cross-over) and according to allocation (not including cross-
overed patients).  
 
 
 
 
CT-allocated (n= 225) MRI-allocated (n= 219) p 
Age, years* 70 (26) 70 (24) 0.757 
Male gender 97 (44.1%) 118 (53.9%) 0.030 
NIHSS admission* 3 (7) 3 (6) 0.838 
mRS before onset* 1 (2) 1 (2) 0.743 
mRS at 3 month 
(median, IQR) 
2 (3.0) 2 (2.0) 0.398 
Independent living at 3 
months (mRS<3) 
116 (51.6%) 110 (50.2%) 0.891 
Mortality at 3 months 26 (10.2%) 19 (8.7%) 0.477 
Atrial fibrillation 35 (15.6%) 40 (18.3%) 0.552 
Hypertension 91 (40.4%) 86 (39.3%) 0.876 
Hypercholesterolemia 56 (24.9%) 47 (22.4%) 0.457 
Diabetes melitus 19 (8.4%) 26 (11.9%) 0.299 
Previous stroke/TCI 52 (23.1%) 54 (24.7%) 0.787 
Alcohol abuse 23 (10.2%) 21 (9.6%) 0.974 
Use of tobacco 47 (20.9%) 42 (19.2%) 0.777 
Thrombolysis 75 (33.3%) 65 (29.7%) 0.468 
Door-needle-time 22 (15.5) 30 (14) 0.004 
Discharge diagnosis    
Ischemic stroke 96 (43.6%) 89 (40.6%) 0.736 
Transient Ischaemic 
Attack 
40 (17.8%) 42 (19.2%) 0.797 
ICH 15 (6.7%) 22 (10.0%) 0.264 
Stroke-mimic  74 (32.9%) 66 (30.1%) 0.502 
Radiological scores:     
Relative signs of iv-tPA 
treatable hyper acute 
ischemia 
28 (12.4 %) 37 (16.9 %) 0.233 
Relative radiological iv-
tPA contraindications 
30 (13.3 %) 37 (16.9 %) 0.360 
Findings considered to 
increase the risk of iv-
tPA treatment 
82 (36.4 %) 83 (37.9 %) 0.827 
 
Table 2, Baseline-characteristics according to image-allocation (intention-to-treat), *median (IQR) 
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 CT performed n= 310 MRI performed n= 134 p 
Age* 73.5 (22) 63.5 (29.25) 0.001 
Male gender 148 (47.7%) 67 (50%) 0.739 
NIHSS admission* 4 (10) 2 (5) 0.001 
mRS before onset* 1 (3) 0 (1) 0.001 
Atrial fibrillation 56 (18.1%) 19 (14.2%) 0.387 
mRS at 3 month 
(median, IQR) 
2 (3.0) 1 (2.25) 0.001 
Independent living at 3 
months (mRS<3) 
149 (48.1%) 77 (57.5%) 0.001 
Mortality at 3 months 40 (12.9%) 5 (3.7%) 0.009 
Hypertension 134 (43.2%) 43 (32.1%) 0.036 
Hypercholesterolemia 76 (24.5%) 27 (20.1%) 0.380 
Diabetes melitus 36 (11.6%) 9 (6.7%) 0.162 
Previous stroke/TCI 77 (24.9%) 29 (21.6%) 0.546 
Alcohol abuse 32 (10.3%) 12 (9.0%) 0.798 
Use of tobacco 62 (20.0%) 77 (57.5%)  0.980 
Thrombolysis 107 (34.5%) 33 (24.6%) 0.051 
Door-needle-time 23 (16.5) 34 (14) 0.001 
Discharge diagnosis:    
Ischemic stroke 140 (45.2%) 45 (33.6%) 0.030 
Transient Ischaemic 
Attack 
54 (17.4%) 28 (20.9%) 0.463 
ICH 29 (9.4%) 8 (6.0%) 0.319 
Stroke-mimic 87 (28.1%) 53 (39.6%) 0.023 
Radiological scores:    
Relative signs of iv-tPA 
treatable hyper acute 
ischemia 
43 (13.9 %) 22 (16.4 %) 0.582 
Relative radiological iv-
tPA contraindications 
39 (12.6 %) 28 (20.9%) 0.036 
Findings considered to 
increase the risk of iv-
tPA treatment 
120 (38.7%) 45 (33.6%) 0.358 
 
Table 3, Baseline-characteristics according to conducted-imaging (per protocol), *median (IQR) 
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 CT-examined iv-tPA-treated 
patients  
(n=107) 
MRI-examined iv-tPA-treated 
patients 
(n=33) 
p 
Mortality within 3 months 15 (14.0 %) 4 (12.1 %) 0.787 
mRS < 3 at 3 months 63 (58.9 %) 24 (72.7 %) 0.184 
Median mRS (IQR) at three 
months 
2 (3) 1 (2) 0.068 
Any ICH detected on 
control imaging 24 hours 
after iv-tPA-treatment 
5 (4.7 %) 1 (3.0 %) NA 
sICH at 24 hours    
 NINDS criteria 1*(0.9 %) 1 (3.0 %) NA 
 ECASS criteria 1*(0.9 %) 0 NA 
 SITS-MOST criteria 1*(0.9 %) 0 NA 
 
Table 4, Symptomatic ICH (sICH) detected at 24 hours and mRS and mortality at 3 month. *The same patient 
fulfilling all three sICH-criteria  
 
 
 CT-examined patients 
n=229 (310) 
MRI-examined patients 
n=104 (134) 
p 
Image-contribution 7.5 (2.5) 8.2 (1.9) 0.002 
Clinical-contribution 8.3 (2.1) 8.3 (2.0) 0.915 
Certainty of 
prescribing or 
refraining from iv-tPA- 
treatment 
8.6 (1.6) 9.0 (1.2) 0.014 
 
Table 5, Visual-Analogue-Scale scores for CT and MRI-examined patients.  
According to conducted imaging (per-protocol). Patients with missing VAS-scores are not included into this 
analysis equalizing the difference between n and the (bracket total number of patients). Mean, standard-
deviation.   
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95.0 %  
Confidence interval  
Sig. Estimate Std. Error Lower  Upper  
Intercept 1.361 0.561 0.556 2.466 .016 
CT-examination # .260 .169 -0.072 0.583 .125 
Age  -0.001 .004 -.072 .593 .758 
Female gender  -0.410 .144 -.692 -.128 .046 
NIHSS on admission 0.002 .014 -.024 .0291 .862 
Pre-onset mRS  0.002 .005 -.008 .013 .677 
Thrombolysis not prescribed 0.965 .166 0.634 1.205 .001 
Neurological consultant* 0.496 .379 -.309 1.301 .209 
Neurological resident* -0.047 .343 -.753 0.659 .892 
Number of patients per shift -.093 .062 -.223 .037 .160 
Minutes to arrival of next 
patient§ 
-0.011 .020 -.050 .029 .588 
Image-findings(VAS score) .458 .030 .040 .516 .0001 
Clinical-findings (VAS score) .532 .030 .474 .591 .0001 
No radiological signs for iv-tPA-
treatment  
-.390 .223 .828 0.048 .081 
No radiological signs against iv-
tPA-treatment  
-.263 .224 -.704 0.178 .241 
Radiological signs of increased 
risk of iv-tPA-induced ICH  
-.156 .161 -.474 .162 .336 
 
Table 6. Random-effect-model predicting the level of iv-tPA treatment-certainty.   
The analysis allows for the cluster-effect of the 24 stroke-physicians each seeing more than one patient.   
#Versus MRI-examination 
*Versus a Senior-Neurological-Stroke Consultant 
§Intervals of 20 minutes 
 
 
 
 
